Welcome to our dedicated page for Korro Bio SEC filings (Ticker: KRRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Korro Bio, Inc. (KRRO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer listed on Nasdaq. Korro focuses on RNA-editing genetic medicines, and its filings with the U.S. Securities and Exchange Commission offer detailed information on clinical programs, collaborations, restructuring actions, and executive changes that complement its press releases.
Investors can review Forms 10-K and 10-Q for narrative and financial discussion of Korro’s development of KRRO-110 for Alpha-1 Antitrypsin Deficiency, the REWRITE Phase 1/2a clinical trial design, and the OPERA RNA editing platform. These periodic reports also describe risk factors, research and development spending, and collaboration revenue, including from its research collaboration and license agreement with Novo Nordisk A/S.
Current reports on Form 8-K are particularly relevant for tracking material events at Korro. Recent 8-K filings describe the amendment to the Novo Nordisk collaboration establishing a 12‑month pause in research and development activities, strategic restructuring and workforce reductions intended to extend cash runway, and executive transitions such as the resignation of the Chief Financial Officer and Chief Medical Officer and related separation agreements. Other 8-Ks outline compensatory arrangements, including amended employment agreements and equity awards.
Users can also monitor proxy statements and compensation disclosures referenced in Korro’s 8-Ks for background on executive employment terms, as well as any Form 4 insider transaction reports that may be filed to reflect equity grants or option exercises under the company’s stock plans. Stock Titan enhances these filings with AI-powered summaries that explain key points in accessible language, highlight important sections of long reports, and help readers quickly understand how new filings may relate to Korro’s RNA-editing pipeline, collaborations, and capital allocation.
Korro Bio, Inc. Schedule 13G/A shows Deep Track Capital, Deep Track Biotechnology Master Fund, Ltd., and David Kroin jointly report beneficial ownership of 277,966 common shares, equal to 2.96% of the company's outstanding common stock. The filers report no sole voting or dispositive power and shared voting and dispositive power for the full amount, and include a certification that the shares were not acquired to change or influence control. The percentage is calculated using 9,390,492 shares outstanding as referenced in the issuer's disclosure.
AllianceBernstein L.P. reports beneficial ownership of 7,700 shares of Korro Bio Inc. common stock, representing 0.1% of the class. The filing states AllianceBernstein has sole voting and sole dispositive power over all 7,700 shares and holds the position in client discretionary investment advisory accounts for investment purposes. The filing notes AllianceBernstein is majority owned by Equitable Holdings but operates under independent management and that Equitable reports ownership separately. The statement affirms the position was not acquired to influence control of Korro Bio.
Korro Bio reported clinical progress alongside continued cash burn. The company recognized $4.0 million of collaboration revenue from Novo Nordisk and reported dosing of first participants in its Phase 1/2a REWRITE trial of KRRO-110 for Alpha-1 Antitrypsin Deficiency, with interim single-ascending dose data expected in the second half of 2025 and orphan drug designations from the FDA and EMA. As of June 30, 2025 the company held $119.6 million of cash, cash equivalents and marketable securities, which management expects will fund operations into 2027.
However, losses remain significant: net loss was $49.2 million for the six months ended June 30, 2025 and the accumulated deficit was $315.7 million. Management executed a 19% workforce reduction and recorded severance charges. The balance sheet shows total assets of $180.4 million and operating lease liabilities with a present value of $44.6 million. The company states additional financing may be required to continue development.
Korro Bio, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025 as Exhibit 99.1 to a Form 8-K and included a Cover Page Interactive Data file as Exhibit 104. The Form 8-K states the press release is being furnished and expressly notes that the information, including Exhibit 99.1, is not to be deemed "filed" for purposes of Section 18 of the Securities Exchange Act.
The 8-K itself contains no financial figures or tables; readers must review Exhibit 99.1 for the company’s reported results. The report also confirms Korro’s common stock trades under the symbol KRRO on The Nasdaq Capital Market.